By CNBCTV18.com Jan 14, 2022 11:06:01 PM IST (Updated)
Follow real-time updates on Union Budget 2023Catch exclusive videos on Union Budget 2023 from CNBC-TV18
SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.
Drugs Controller General of India (DCGI)'s Subject Expert Committee on Friday sought more data from Bharat Biotech and Serum Institute of India (SII) before granting full market approval to Covaxin and Covishield, said sources.
Recommended Articles
View All
World Cancer Day 2023: Early detection is crucial for reducing the global burden
Feb 4, 2023 IST5 Min(s) Read
World Cancer Day 2023: A way forward to better management of cancer this year!
Feb 4, 2023 IST6 Min(s) Read
Pakistan economy at alarming level as foreign reserves drop to $3.1 billion from $16.6 billion in a year
Feb 3, 2023 IST3 Min(s) Read
FM Nirmala Sitharaman speaks on inflation, taxes, GDP and more. Read the full interview here
Feb 3, 2023 IST37 Min(s) Read
Sources added that SII and Bharat Biotech can't be allowed to sell Covaxin and Covishield in open market till government is mapping vaccination through specific nationwide drive via Cowin App.
SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.
However, both Covaxin and Covishield are currently authorized for emergency use only. EUA does not represent approval of a vaccine in the full statutory term but authorises the use of an unapproved product or unapproved use of an approved product in a declared state of emergency such as a pandemic. A market authorisation label for a vaccine means it can be authorised for use without reservations or conditions.
(Edited by : Aditi Gautam)
First Published: Jan 14, 2022 10:56 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!